Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06556173
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
Phase 2a Study of VTX3232 in Parkinsons Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2a Single Site Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of VTX3232 in Participants With Early-Stage Parkinsons Disease
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinsons Disease PD Approximately 10 patients will take VTX3232 Dose A
The study consists of a 30-day Screening Period to see if a participant qualifies for the study a 7-day Pre-Baseline Period a 28-day Open Label Treatment period a participant receives active Dose A and a 14-day Follow-Up Period
The study consists of a 30-day Screening Period to see if a participant qualifies for the study a 7-day Pre-Baseline Period a 28-day Open Label Treatment period a participant receives active Dose A and a 14-day Follow-Up Period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None